Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of QBECO SSI for the Induction and Maintenance of Clinical and Endoscopic Remission in Subjects With Moderate to Severe Crohn's Disease

Trial Profile

A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of QBECO SSI for the Induction and Maintenance of Clinical and Endoscopic Remission in Subjects With Moderate to Severe Crohn's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs QBECO (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RESTORE
  • Sponsors Qu Biologics
  • Most Recent Events

    • 13 Nov 2018 According to a Qu Biologics media release, 10 of the 20 patients to be included in the first stage of this trial have been enrolled in the study. The endoscopic remission/response data from the trial is anticipated in Q2 2019.
    • 25 Jul 2018 According to a Qu Biologics media release, first patient has been enrolled in the open label stage of this trial.
    • 09 Jul 2018 Planned End Date changed from 30 Apr 2019 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top